Keyword: Johnson & Johnson
InVivo Therapeutics, which specializes in spinal cord injuries, names Richard Toselli, M.D., as its president and chief executive.
The partnership brings together J&J’s antibodies and a university’s AAVs in a bid to open up a new frontier in the fight against the disease.
The involvement of the Big Pharmas helped BGV blast past its target, leaving it with €82 million to invest in life science companies in Europe.
XW Laboratories has seen a $17.5 million series B, bumping up its total raise from its first round to $23 million.
Kura Oncology shares are up 75% after the biotech reported hitting the mark in a phase 2 trial of tipifarnib—before the study was fully enrolled.
J&J has unveiled another clutch of deals and collaborations with industry and academia.
Actelion has posted mixed late-phase data on its antibiotic cadazolid.
Attorney General Andy Beshear filed a lawsuit this week in Franklin Circuit Court in Kentucky against Johnson & Johnson and it’s medical device unit Ethicon. The suit claims deceptive marking of surgical transvaginal mesh under the Kentucky Consumer Protection Act.